CytomX Therapeutics, Inc. (CTMX)

Market Cap	748.82M +1,365.4%
Revenue (ttm)	76.20M -44.8%
Net Income	-20.37M
EPS	-0.15
Shares Out	170.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,720,582
Open	5.270
Previous Close	5.450
Day's Range	4.360 - 5.310
52-Week Range	0.400 - 8.210
Beta	2.48
Analysts	Strong Buy
Price Target	11.30 (+156.82%)
Earnings Date	Mar 16, 2026

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2015
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: CTMX
• Website: https://www.cytomx.com

Analyst Summary

According to 10 analysts, the average rating for CTMX stock is "Strong Buy." The 12-month stock price target is $11.3, which is an increase of 156.82% from the latest price.

Price Target

$11.3

(156.82% upside)

Analyst Consensus: Strong Buy